The market for central nervous system prescription drugs grew 21.3% to reach $62.4 billion in 2003. The growth of this massive market is due to companies accessing previously untapped patient groups and several advances in drug technology. Given the increasing Industry interest in a multitude of commercial opportunities, the expansion of CNS is expected to continue unabated.
Scope of this report
Commercial performance of each key CNS drug for every analyzed company over the last two years
Analysis of company positioning in psychiatry, neurology and pain management
Analysis of each company’s late stage pipeline and identification of key R&D projects
Areas for expansion, in terms of both new markets and product line extensions, are analyzed, discussed and recommended for each company
Research and analysis highlights
Pfizer’s CNS portfolio is the best in the Industry with a strong presence in all major areas and a promising late stage pipeline. The value of its franchise is double that of the next largest portfolio and it boasts blockbuster products in all three sectors of CNS: psychiatry, neurology, and pain.
The closest CNS portfolio to Pfizer’s in terms of breadth is J&J’s. The company performs well in all three sectors of CNS with blockbuster products in each; namely Risperdal (psychiatry), Duragesic (pain), and Topamax (neurology).
Co-licensing agreements are becoming standard practice for leading CNS players. Combining the broad marketing reach of a top tier company with the therapy expertise of a specialist company is becoming ever important in a tough market climate.
Key reasons to read this Report :
Benchmark your CNS portfolio against the current leading portfolios and understand what makes a commercially successful CNS portfolio
Identify up to date issues impacting the CNS franchises of leading players
Recognize the key drugs in each company portfolio, and which offer the best commercial opportunities
To know more and to buy a copy of your report feel free to visit: http://www.bharatbook.com/Market-Research-Reports/Top-CNS-Portfolios-The-Industry-Gold-Standards.html
Or
Contact us at:
Bharat Book Bureau
Tel: +91 22 2757 8668
Fax: +91 22 2757 9131
Email: info@bharatbook.com
Website: www.bharatbook.com
Blog: http://bharatbookresearch.blogspot.com |
